Acticor Biotech (XPAR:ALACT) Change In Receivables : €0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Change In Receivables?

Acticor Biotech's change in receivables for the quarter that ended in Jun. 2023 was €0.00 Mil. It means Acticor Biotech's Accounts Receivable stayed the same from Dec. 2022 to Jun. 2023 .

Acticor Biotech's change in receivables for the fiscal year that ended in Dec. 2022 was €0.00 Mil. It means Acticor Biotech's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .

Acticor Biotech's Accounts Receivable for the quarter that ended in Jun. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Acticor Biotech's liquidation value for the six months ended in Jun. 2023 was €-5.98 Mil.

Acticor Biotech Change In Receivables Historical Data

The historical data trend for Acticor Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Change In Receivables Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

0.91

-0.93

-0.67

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial				-0.87	-	-	-	-

Acticor Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Acticor Biotech (XPAR:ALACT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Acticor Biotech's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Acticor Biotech's accounts receivable are only considered to be worth 75% of book value:

Acticor Biotech's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.955	-	13.934	+	0.75 * 0	+	0.5 * 0
=	-5.98

Acticor Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (XPAR:ALACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

7V7:Germany

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines